Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation

Blood

Volumn 119, Issue 21, 2012, Pages 5030-5036

  Chaidos, Aristeidis ^a,b   Patterson, Scott ^a,b   Szydlo, Richard ^a,b   Chaudhry, Mohammed Suhail ^a,b   Dazzi, Francesco ^a,b   Kanfer, Edward ^a,b   McDonald, Donald ^a,b   Marin, David ^a,b   Milojkovic, Dragana ^a,b   Pavlu, Jiri ^a,b   Davis, John ^a,b   Rahemtulla, Amin ^a,b   Rezvani, Katy ^a,b   Goldman, John ^a,b   Roberts, Irene ^a,b   Apperley, Jane ^a,b   Karadimitris, Anastasios ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLOSPORIN A; GAMMA INTERFERON; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MIXED LYMPHOCYTE REACTION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NATURAL KILLER T CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SEZARY SYNDROME; T LYMPHOCYTE; WHOLE BODY RADIATION;

EID: 84860652954     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-389304     Document Type: Article

References (37)

1. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297-336. (Pubitemid 46697911)
2. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 2002;195(5):625-636. (Pubitemid 34461507)
3. Kohrt HE, Pillai AB, Lowsky R, Strober S. NKT cells, Treg, and their interactions in bone marrow transplantation. Eur J Immunol. 2010;40(7):1862- 1869.
4. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol. 2011;11(2):131-142.
5. Chakraverty R, Sykes M. The role of antigenpresenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood. 2007; 110(1):9-17. (Pubitemid 47026813)
6. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009; 373(9674):1550-1561.
7. Apperley JF, Jones L, Hale G, et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant. 1986;1(1):53-66. (Pubitemid 17070365)
8. Yamasaki S, Henzan H, Ohno Y, et al. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors. Bone Marrow Transplant. 2003;32(5):505-510. (Pubitemid 37160966)
9. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease. Blood. 2009;114(24):4919-4927.
10. Pabst C, Schirutschke H, Ehninger G, BornhauserM, Platzbecker U. The graft content of donor T cells expressing gamma delta TCR+ and CD4+ foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors. Clin Cancer Res. 2007;13(10):2916-2922. (Pubitemid 46849566)
11. Wolf D, Wolf AM, Fong D, et al. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation. 2007;83(8):1107-1113. (Pubitemid 46659123)
12. Lan F, Zeng D, Higuchi M, Higgins JP, Strober S. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versushost disease: the role of CD1-reactive natural killer T cells. Biol Blood Marrow Transplant. 2003; 9(6):355-363. (Pubitemid 38351806)
13. Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med. 2005;353(13):1321-1331. (Pubitemid 41362700)
14. Morris ES, Macdonald KP, Rowe V, et al. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest. 2005;115(11):3093-3103. (Pubitemid 41567574)
15. Kuwatani M, Ikarashi Y, Iizuka A, et al. Modulation of acute graft-versus-host disease and chimerism after adoptive transfer of in vitro-expanded invariant Valpha14 natural killer T cells. Immunol Lett. 2006;106(1):82-90. (Pubitemid 44093057)
16. Yang J, Gao L, Liu Y, et al. Adoptive therapy bytransfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation. Transfusion. 2010;50(2):407-417.
17. Leveson-Gower DB, Olson JA, Sega EI, et al. Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. Blood. 2011;117(11): 3220-3229.
18. Mohty M, Szydlo RM, Yong ASM, Apperley JF, Goldman JM, Melo JV. Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. Blood. 2008;112(5): 2163-2166.
19. Gray RJ. A Class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
20. Jason PF, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
21. Exley MA, Tahir SM, Cheng O, et al. A major fraction of human bone marrow lymphocytes are Th2- like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J Immunol. 2001; 167(10):5531-5534. (Pubitemid 33062739)
22. Hahn T, McCarthy PL Jr, Zhang MJ, et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol. 2008;26(35):5728-5734.
23. Flowers MED, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute and for chronic graft-versus-host-disease according to National Institute of Health consensus criteria. Blood. 2011;117(11):3214-3219.
24. Nash RA, Pepe MS, Storb R, et al. Acute graftversus- host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992;80(7):1838-1845.
25. Storb R, Prentice RL, Buckner CD, et al. Graftversus- host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. N Engl J Med. 1983; 308(6):302-307. (Pubitemid 13179412)
26. Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119(1): 296-307.
27. Crough T, Nieda M, Nicol AJ. Granulocyte colonystimulating factor modulates alpha-galactosylceramide-responsive human Valpha24+Vbeta11+NKT cells. J Immunol. 2004;173(8):4960-4966. (Pubitemid 39387778)
28. Michonneau D, Peffault de LR, Porcher R, et al. Influence of bone marrow graft B lymphocyte subsets on outcome after HLA-identical sibling transplants. Br J Haematol. 2009;145(1):107-114.
29. Cao TM, Wong RM, Sheehan K, et al. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen- identical peripheral blood allografting for hematologic malignancies. Exp Hematol. 2005; 33(3):279-285. (Pubitemid 40261309)
30. Urbano-Ispizua A, Rozman C, Pimentel P, et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood. 2002;100(2):724-727. (Pubitemid 34761147)
31. Stanzani M, Martins SLR, Saliba RM, et al. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versushost disease after HLA-identical stem cell transplantation in humans. Blood. 2004;103(3):1140- 1146.
32. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3): 1061-1070.
33. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GvHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011; 117(14):3921-3928.
34. Patterson S, Chaidos A, Neville DC, et al. Human invariant NKT cells display alloreactivity instructed by invariant TCR-CD1d interaction and killer Ig receptors. J Immunol. 2008;181(5):3268- 3276.
35. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100. (Pubitemid 34229476)
36. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412-415. (Pubitemid 29343964)
37. Exley MA, Nakayama T. NKT-cell-based immunotherapies in clinical trials. Clin Immunol. 2011; 140(2):117-118.